Get the current market patterns in your inbox
Remain on top of the most recent market patterns and financial insights with the Axios Markets newsletter. Sign up for totally free.
Catch up on coronavirus stories and unique reports, curated by Mike Allen everyday
Capture up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your home town with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most essential stories impacting your home town with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Capture up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Image: Pavlo Gonchar/SOPA Images/LightRocket via Getty Images
AstraZeneca CEO Pascal Soriot said on Thursday the company is likely to start a new worldwide trial to measure how efficient its coronavirus vaccine is, Bloomberg reports.
Why it matters: Following Phase 3 trials, Oxford and AstraZeneca stated their vaccine was 90?ficient in people who got a half dose followed by a full dose, and 62?fective in people who got two full dosages.
- ” Now that we have actually found what appears like a better efficacy we need to validate this, so we require to do an extra study,” Soriot stated, in his first interview because the University of Oxford revealed data today from the vaccine it’s developing with AstraZeneca.
Soriot told Bloomberg that it would likely be another “worldwide research study, but this one could be much faster because we know the effectiveness is high so we require a smaller sized number of patients.”
- Soriot does not expect the trial to impact regulatory approvals in the European Union and the U.K., although FDA clearance may take longer, he stated.
Comments
Post a Comment